- Home
- PVLA vs NUS Comparison
PVLA vs NUS Comparison
Compare PVLA & NUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVLA
- NUS
- Stock Information
- Founded
- PVLA 2015
- NUS 1984
- Country
- PVLA United States
- NUS United States
- Employees
- PVLA N/A
- NUS N/A
- Industry
- PVLA Biotechnology: Pharmaceutical Preparations
- NUS Other Pharmaceuticals
- Sector
- PVLA Health Care
- NUS Health Care
- Exchange
- PVLA Nasdaq
- NUS Nasdaq
- Market Cap
- PVLA 308.2M
- NUS 308.1M
- IPO Year
- PVLA N/A
- NUS 1996
- Fundamental
- Price
- PVLA $24.36
- NUS $5.48
- Analyst Decision
- PVLA Strong Buy
- NUS Hold
- Analyst Count
- PVLA 7
- NUS 2
- Target Price
- PVLA $44.43
- NUS $6.88
- AVG Volume (30 Days)
- PVLA 97.9K
- NUS 741.4K
- Earning Date
- PVLA 05-15-2025
- NUS 05-08-2025
- Dividend Yield
- PVLA N/A
- NUS 4.28%
- EPS Growth
- PVLA N/A
- NUS N/A
- EPS
- PVLA N/A
- NUS N/A
- Revenue
- PVLA N/A
- NUS $1,732,084,000.00
- Revenue This Year
- PVLA N/A
- NUS N/A
- Revenue Next Year
- PVLA N/A
- NUS N/A
- P/E Ratio
- PVLA N/A
- NUS N/A
- Revenue Growth
- PVLA N/A
- NUS N/A
- 52 Week Low
- PVLA $6.20
- NUS $5.60
- 52 Week High
- PVLA $29.27
- NUS $14.00
- Technical
- Relative Strength Index (RSI)
- PVLA N/A
- NUS 29.06
- Support Level
- PVLA N/A
- NUS $5.75
- Resistance Level
- PVLA N/A
- NUS $6.65
- Average True Range (ATR)
- PVLA 0.00
- NUS 0.38
- MACD
- PVLA 0.00
- NUS -0.12
- Stochastic Oscillator
- PVLA 0.00
- NUS 6.31
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. It is developing a broad pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases. Palvella's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations.
About NUS Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.